Key Highlights:
- ClearOne shares rose 12.54% to $2.16 on Friday, October 23, 2026.
- The merger agreement dated July 1, 2026 gives Vivani Medical 12,500,000 shares, or about 77.98% of the combined company.
- Existing ClearOne holders would own about 16.69%, or 2,675,412 shares.
- A financing of $10.0 million to $15.0 million is a closing condition.
- The second-quarter net loss was $914,000, compared with $4.572 million a year earlier.
ClearOne Stock: What Is Behind the 13% Rise While the Cortigent Merger Is Pending?
ClearOne (NASDAQ:CLRO) shares rose 12.54% to $2.16 on Friday, October 23, 2026. The company has not announced a catalyst for the session, and the merger with Cortigent has not been reported as closed.
The deal remains the central driver of the stock. Under a merger agreement dated July 1, 2026, a ClearOne subsidiary will merge into Cortigent, which will survive as a wholly owned subsidiary. The announcement on July 2 was followed by a sharp rally, with the stock reaching an intraday high near $9.62 that day, according to market reports.
The shares have since given back much of that gain. A market estimate put the price at $4.06 on October 6, so the stock was well below that level before the October 23 rise, and the company has not explained the decline.
What Are the Terms of the Cortigent Merger?
Vivani Medical (NASDAQ:VANI) will receive 12,500,000 ClearOne shares for all of its Cortigent equity, a fixed number with no earnout or price-based milestones. Cortigent is a neurostimulation business spun out of Vivani and focused on brain-computer interface technology.
After closing, and before the financing, Vivani would hold about 77.98%, existing ClearOne holders about 16.69% and advisors about 5.33% of 16,030,412 shares (per the information statement). Half of Vivani's shares are locked up for one year and half for two years.
ClearOne is expected to be renamed Cortigent Holdings and trade on Nasdaq under the ticker CRGT. A majority holder approved the transaction by written consent on August 3, 2026.
What Must Happen Before the Deal Can Close?
The company must raise $10.0 million to $15.0 million gross through units that are expected to include one share and one warrant, and Nasdaq must approve the combined company's initial application. Either party may terminate if the merger is not completed within 180 days of signing, which points to late December 2026 (calculated).
Vivani had been reported in September as expecting the transaction to be priced and closed in October 2026. The company has not announced a closing date, and the information statement does not set one.
What Do ClearOne's Own Financials Look Like?
ClearOne's second-quarter net loss was $914,000, or $0.34 per share, compared with $4.572 million, or $2.64 per share, a year earlier. First-half net loss was $1.401 million, down from $7.406 million.
Cash was $75,000 on June 30, and total liabilities were $1.371 million. A market estimate put the market value at $10.8 million at $4.06 on October 6, which implies about 2.66 million shares (calculated), so the value at $2.16 would be about $5.7 million (calculated).
The 52-week range is $2.71 to $16.50.
What to Watch Next: Will the Cortigent Merger Close Before Year-End?
ClearOne rose 12.54% on October 23 without an announced catalyst, and its outlook depends on the financing and Nasdaq approval needed to complete the Cortigent merger. The next dated checkpoint is the termination right that arises in late December 2026 if the merger has not closed; the company has not announced a closing date or a third-quarter reporting date.
Shares rose 12.54% to $2.16, and the company has not announced a catalyst for the session.
Vivani Medical will receive 12,500,000 ClearOne shares, about 77.98% of the combined company before a $10 million to $15 million financing.
It is expected to become Cortigent Holdings and trade on Nasdaq as CRGT.






Please wait processing your request...